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Abstract
Background: Plantar warts (verrucae) are extremely common. Although many will spontaneously disappear
without treatment, treatment may be sought for a variety of reasons such as discomfort. There are a number of
different treatments for cutaneous warts, with salicylic acid and cryotherapy using liquid nitrogen being two of the
most common forms of treatment. To date, no full economic evaluation of either salicylic acid or cryotherapy has
been conducted based on the use of primary data in a pragmatic setting. This paper describes the cost-
effectiveness analysis which was conducted alongside a pragmatic multicentre, randomised trial evaluating the
clinical effectiveness of cryotherapy versus 50% salicylic acid of the treatment of plantar warts.
Methods: A cost-effectiveness analysis was undertaken alongside a pragmatic multicentre, randomised controlled
trial assessing the clinical effectiveness of 50% salicylic acid and cryotherapy using liquid nitrogen at 12 weeks after
randomisation of patients. Cost-effectiveness outcomes were expressed as the additional cost required to
completely cure the plantar warts of one additional patient. A NHS perspective was taken for the analysis.
Results: Cryotherapy costs on average £101.17 (bias corrected and accelerated (BCA) 95% CI: 85.09-117.26) more
per participant over the 12 week time-frame, while there is no additional benefit, in terms of proportion of patients
healed compared with salicylic acid.
Conclusions: Cryotherapy is more costly and no more effective than salicylic acid.Trial registration
Current Controlled Trials ISRCTN18994246 [controlled-trials.com] and National Research Register N0484189151.
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Background
Plantar warts (verrucae) are extremely common, and are
experienced by most people at some time during their
lives [1,2]. Many will spontaneously disappear without
treatment [3]. However, treatment may be sought for a
variety of reasons, such as discomfort or being pre-
vented from undertaking sports or activities of daily
living. There are a number of different treatments for
plantar warts. In the UK the first line of treatment is
generally an over-the-counter (OTC) salicylic acid pre-
paration at strength of 15-26%. Second line treatments
include cryotherapy treatment using liquid nitrogen and
higher concentrations of salicylic acid for example 50%
salicylic acid. Other treatments such as surgical curet-
tage, complementary and alternative therapies are also
available; however, there is a very little evidence to sup-
port the use of any of these treatments [4]. Even after
treatment some plantar warts may fail to resolve, or
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rates of cutaneous warts vary between 19% [5] following
treatment with cryotherapy to around 30% [4] following
surgical removal.
The treatment of warts represents a considerable cost
burden to both patients and the NHS. In the literature
[6], it has been indicated that, based on National Morbid-
ity Survey data (1991-2), almost 2 million people in Eng-
land and Wales see their General Practitioner (GP) for
the treatment of cutaneous (non-genital) warts each year,
at a cost of at least £40 million per annum. Economic
analyses of salicylic acid and cryotherapy, alongside a
wide range of other treatments in the UK setting, have
been conducted by employing decision analytic modelling
and synthesising data from a variety of sources [7,8].
These demonstrated that the most cost-effective treat-
ments were over-the-counter (OTC) treatments; either
salicylic acid or self-administered cryotherapy kits, bought
by patients and applied in the patients’ homes. Of the
treatments provided in a primary care setting, the most
cost-effective treatments were salicylic acid and cryother-
apy delivered by a nurse. Both had similar cost-effective-
ness values, but this was based on the assumption that
patients would not receive more than three cryotherapy
treatments, at two weekly intervals.
To date, no reports of a full economic evaluation of
either salicylic acid or cryotherapy conducted based on
the use of primary data, in a pragmatic setting, have
been identified. This would increase the confidence in
the conclusions on the cost-effectiveness of the treat-
ments. Hence, an economic evaluation was conducted
alongside a randomised controlled trial to investigate
both the clinical and cost-effectiveness of two second
line treatments; cryotherapy using liquid nitrogen com-
pared with patient self-treatment with 50% salicylic acid.
The clinical results of the trial have been published pre-
viously [9].
Methods
Study design and interventions
Full details of the study design and interventions have
been described in the paper presenting the clinical
results of the EVerT trial [9] and in the study protocol
[10]. Briefly, a multicentre randomised controlled trial
was conducted. Participants aged 12 years and over with
a plantar wart were recruited from University podiatry
school clinics, NHS podiatry clinics, and primary care in
England, Scotland and Ireland. Participants were rando-
mised to receive either up to a maximum of four
cryotherapy treatments using liquid nitrogen, two to
three weeks apart and delivered by a healthcare profes-
sional (podiatrist, practice nurse or General Practi-
tioner), or patient daily self-treatment with 50% salicylic
acid once they were directed on how to apply the
treatment.
The primary outcome was complete clearance of all
plantar warts at 12 weeks after randomization.
The study was approved by Trent multicentre
Research Ethics Committee, Galway Research Ethics
Committee and local ethics committees, Medicines and
Healthcare Products Regulatory Agency, Irish Medicines
Board and local Research and Development Trusts. All
participants provided written informed consent prior to
being enrolled in the study.
Economic analysis
An economic evaluation was conducted at 12 weeks
after randomisation of participants. The aim of the eco-
nomic analysis was to assess the relative costs and effec-
tiveness of cryotherapy and salicylic acid for the
treatment of plantar warts. Trial data on both costs and
effectiveness of the two comparators were synthesised to
assess the additional cost required for an additional unit
of outcome. For this analysis, a cost-effectiveness
approach was taken, where the outcome was defined as
complete clearance of plantar warts at 12 weeks. There
were no utility data collected during the trial which
would allow a cost-utility analysis to be undertaken. No
discounting was applied given that the timeframe of the
analysis was shorter than one year. The analysis was
conducted on an “intention-to-treat” basis. Hence, the
treatment groups were compared based on their original
random allocation, regardless of protocol deviations and
participants’ compliance or withdrawal. The NHS per-
spective was taken for the analysis [11], where only
costs directly linked to the NHS budget (e.g. GP or
nurse visits, podiatrist time and cost of equipment and
medications) were included.
Outcome data
The outcome data used for the economic analysis was
the complete clearance of plantar warts at 12 weeks.
Clearance of plantar warts was defined as the restoration
of normal skin upon close inspection. The data on the
outcome were extracted primarily by two independent
assessors, blinded to treatment allocation, from digital
photographs of the participant’s plantar warts taken at
12 weeks. An additional blinded outcome assessment at
the recruiting site was undertaken at the participant’s1 2
week appointment. This assessment would be used in
the case where the assessment of the digital photograph
was not possible, for example, when the photograph was
not interpretable or missing. If neither of these were
available for a participant, then the patient’ss e l f -
reported outcome recorded in the week 12 question-
naire was used.
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During the participant’s treatment period within the
study, data on the resource usage component of the
economic analysis were collected from both patients’
self-completed questionnaires and the relevant question-
naires completed by the healthcare professionals. Partici-
pants were asked to complete the questionnaire about
the number of visits to the clinic for treatment of their
verruca and any other health service usage (for example,
if they had seen a GP, practice nurse or attended an
emergency visit with a GP due to their verruca). The
number of visits to the podiatrist, nurse or GP for
receiving the relevant treatment, as per the trial protocol
and the randomisation arm, was recorded by the health-
care professional who treated the trial participant. In
particular, details on the number of cryotherapy sessions
administered and the number of tubes of salicylic acid
provided to the patients were collected.
Cost of the cryotherapy treatment
The cost of cryotherapy treatment comprised of three
components: the cost of the equipment (i.e. the initial
investment for purchasing the equipment), the cost of
liquid nitrogen and the opportunity cost of the health-
care professional’s time for attending the patients. The
list of equipment required for cryotherapy is given in
Table 1.
Annuitization of the equipment cost was performed
(Eq.1) for the economic analysis. The cost of the equip-
ment (K), which was incurred upon their purchase, is
spread over the lifetime of the equipment to obtain an
equivalent annual cost (E). An interest rate (r) of 3.5%
and a lifespan (n) for the cryogenic equipment of five
years were used in the calculations of the annuity factor.
K = E
1 − (1 + r)
−n
r
To assign an equipment cost per treatment session,
the annual cost (E) was divided by the maximum num-
ber of treatments that can be provided by the healthcare
professional. The maximum number of treatments was
calculated based on an average appointment time of 20
min and, assuming full capacity of the clinics, for the
total number of working days per year (i.e. 253 exclud-
ing bank holidays in the UK). The average appointment
time of 20 min was based on the experience of podia-
trists and practice nurses.
In addition to the equipment cost, the cost of liquid
nitrogen, the freezing agent for the cryotherapy, was cal-
culated. Liquid nitrogen is a liquid gas with high level of
static evaporation at around 2% per day [13]. Hence, the
liquid nitrogen dewars are refilled frequently, approxi-
mately every four to six weeks, even though the liquid
nitrogen is not being used fully for patient treatments. It
is, therefore, difficult to assess the quantity of liquid
nitrogen that is required for a single treatment. However,
from the trial data, it was noticed that in one trial centre
which exclusively treated trial participants, four refills of
a 25 litre dewar were ordered in a timeframe of three
months. The cost of liquid nitrogen per treatment was
Table 1 Unit cost of cryotherapy equipment
Item Source Size/type Price
a, b Average price Price in £
c Price inc. VAT
d
Cryogenic gloves* BOC catalogue sent to a trial centre € 35 € 35.00 £28.88 £33.94
Safety glasses* BOC Products [12] £4.42 £4.42 £4.42 £5.19
Dewar* BOC catalogue sent to a trial centre 25 litre Aluminium € 833 € 868.00 £716.30 £841.65
25 litre Stainless Steel € 903
Tipping trolley for dewar* BOC catalogue sent to a trial centre € 433 € 433.00 £357.33 £419.86
Withdrawal device* BOC catalogue sent to a trial centre € 708 € 708.00 £584.26 £686.51
Cryosurgery applicator* BOC catalogue sent to a trial centre 330 ml capacity applicator € 630.40 € 642.10 £529.88 £622.61
450 ml capacity applicator € 653.80
Slim probe* BOC catalogue sent to a trial centre 1 mm € 99.40 € 99.40 £82.03 £96.38
2m m € 99.40
3m m € 99.40
Cryogenic* apron BOC Products [12] Small £137.28 £163.02 £163.02 £191.55
Medium £154.44
Large £171.60
Extra large £188.76
a Different prices are provided for different sizes/types of equipment. The average price was calculated
b All the prices reported in Euro refer to 2009/2010 prices
c Exchange rate: 1 € = 0.825232749 GBP (source: Google.co.uk, date 10/06/2010)
d VAT was applied at 17.5%
*List compiled by a combination of interviewing podiatrists running the clinic and equipment bought to set up trial sites
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dewar by the total number of treatments performed in
that centre. Liquid nitrogen costs are given in Table 2.
The clinician’s time was calculated based on an aver-
age appointment time of 20 min. The treatments were
administered to the trial participants either by a GP, a
practice nurse or a podiatrist.
Cost of the salicylic acid treatment
The cost of the salicylic acid treatment comprised of
two components: the cost of the medication and the
health professional’s time spent for each treatment
assessment visit. Unit costs for the salicylic acid medica-
tion, pads and plasters and calculation of the salicylic
acid treatment costs are given in Table 3.
The cost of the healthcare professional’st i m ef o r
explaining treatment administration was calculated
based on an average appointment time of 20 min.
Unit costs of the treatments’ components
The unit costs for the cryotherapy equipment were
retrieved from the British Oxygen Company’s( B O C )
website [12] and from the BOC catalogue that was sent
to the different trial centres. When more than one type
of the same item was available, the average unit cost
was calculated. The unit costs for the cryotherapy
equipment are presented in Table 1.
The cost data that were used for calculating the cost
of liquid nitrogen per treatment were retrieved from the
purchases of liquid nitrogen at a single trial centre. The
costs included the cost of the liquid nitrogen and the
cost of delivery. The average cost over four purchases
was calculated. Details are provided in Table 2.
For the salicylic acid treatment, the unit costs for the
medication, pads and plasters are presented in Table 3.
Unit costs of the healthcare professionals’ time
The unit costs for the healthcare professional’st i m e
were retrieved from the Unit Costs of Health and Social
Care (2009) document published by the Personal Social
Services Research Unit (PSSRU) of Kent University [17].
The Unit Cost of healthcare professional’st i m ew a s
based on their speciality. Unit costs for healthcare pro-
fessionals with the lowest qualifications were chosen.
These are presented in Table 4.
Data analysis and presentation
The method of data analysis was mainly dictated by the
level of missing data for the primary outcome. The base
case analysis (scenario 1) was conducted as a “complete
case analysis” where only patients with available primary
outcome data were included. Where resource use data
were missing, mean values were imputed (i.e. treatments
visits, additional visits to the GP or nurse, number of
cryotherapy treatments, number of tubes of Verrugon).
For the visits to the treating healthcare professional, the
mean imputation was performed based on the outcome
group (i.e. verrucae gone or not gone) and the treatment
allocation. For the cryotherapy treatments and the
Table 2 Cost of liquid nitrogen
Item Source Price
a Average Price in £
b Price inc. VAT
c
Liquid nitrogen (calculated
for 25 litre dewar)
Invoice to one of the trial centres Invoice 1 € 2.79/l
Invoice 2 € 2.79/l
Invoice 3 € 2.48/l
Invoice 4 € 2.48/l € 65.88
Delivery charges Invoice to one of the trial centres Invoice 1 € 38/delivery
Invoice 2 € 38/delivery
Invoice 3 € 16.86/delivery
Invoice 4 € 16.86/delivery € 27.43
Total for liquid nitrogen and
delivery
€ 93.31 £77.00 £90.47
a All the prices reported in Euro refer to 2009/2010 prices
b Exchange rate: 1 € = 0.825232749 GBP (source: Google.co.uk, date 10/06/2010)
c VAT was applied at 17.5%
Table 3 Unit costs and calculation of the medication
costs for the salicylic acid treatment
Item Source Price inc.VAT
a
Verrugon 6 g
b BNF 59 [14] £3.00
Fabric plasters
c Boots the chemist [15]
d £1.49
Pads
c Felt-pads. Product PPD126 [16]
d £2.30
a VAT was applied at 17.5%
b Cost of Verrugon tubes was based on the
number of entire tubes used
c The number of plasters and pads used was
based on the number of applications applied, which in turn was based on the
number of Verrugon tubes used. Patients using one tube of Verrugon
required sufficient plasters and pads for 28 applications. The number of boxes
of felt pads used per patient was calculated by dividing the number of
applications by the total number of pads in a box (36), rounded up to a
whole number. The number of plasters used was calculated by dividing the
number of applications by the number of plasters in a box (20), rounded up
to a whole number.
d Access date 10/06/2010
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imputed based on the outcome group only.
For this scenario, the analysis was conducted based on
1) unadjusted costs and outcomes
2) costs and outcomes adjusted for a number of cov-
ariates: age of the participants, whether or not they
had received previous treatments and the type of
plantar warts.
An additional analysis (scenario 2) was conducted by
including all the patients (with and without primary out-
come data). Data were imputed by using multiple impu-
tation methods for the 11 patients who had missing
primary outcome data. The multiple imputations were
performed by using age, previous treatment and type of
verrucae as covariates on both primary outcome and
missing total costs.
For both analyses, the mean differences in costs and
effects and the 95% confidence intervals around those
were calculated by using bootstrap methods [18] (bias
corrected and accelerated). For the mean difference in
costs, a linear regression was used whilst for the differ-
ence in primary outcome logistic regression was used,
given the binary nature of the data.
The cost-effectiveness of cryotherapy versus salicylic
acid was assessed by comparing the incremental costs
between the two arms of the trial to the incremental
benefit which is expressed as the difference in the pro-
portion of patients with completely cleared plantar
warts at 12 weeks. The incremental cost-effectiveness
ratio (ICER) was calculated by dividing the mean incre-
mental cost (ΔC) by the mean incremental effect (ΔE)
(ICER = ΔC/ΔE). For ease of interpretation of the
results and to accommodate the uncertainty surround-
ing the estimation of costs and outcomes, the net mone-
tary benefits were estimated for a range of willingness-
to-pay thresholds (i.e. the amount that the decision
maker is willing to pay for an additional unit of out-
come) together with the uncertainty around the net
benefit estimates. These are presented graphically using
cost-effectiveness acceptability curves (CAECs) [19],
which show the probability that the new intervention is
cost-effective versus the comparator for a range of
decision makers’ willingness-to-pay thresholds for an
additional unit of outcome.
All the analyses were conducted using STATA statistic
and data analysis software, Version 10.1.
Sensitivity analysis
Sensitivity analysis in the base case scenario was carried
out by adopting an extreme approach whereby the
administration of the treatment was assumed to be done
b yan u r s e( r a t h e rt h a naG P )i nt h o s es t u d ys i t e st h a t
were set up in GP practices, and by excluding comple-
tely the cost of cryotherapy equipment and liquid nitro-
gen. The cost of salicylic acid was retained. In effect,
this analysis would result in comparing both treatments
based on the treatment visits and the cost of salicylic
acid, rather than including the cost of cryotherapy medi-
cation as well. The decision to conduct this sensitivity
analysis was led by the assumption that the costs will be
driven by the healthcare professional’s time and the cost
of the treatment itself (i.e. the cost of the equipment
and that of liquid nitrogen for the cryotherapy arm).
Results
Missing data
Missing data on resource usage relating to additional GP
or nurse visits was 30% and 28% for the cryotherapy and
salicylic acid groups, respectively. The level of missing
data for treatment visits, number of tubes of salicylic
acid and cryotherapy applications was much lower ran-
ging from 2% to 7%.
The missing items were a result of either the trial par-
ticipants not returning the questionnaire or not com-
pleting the relevant questions on the questionnaire.
Missing data on number of treatment visits was due to
missing podiatrist treatment assessment forms where
these visits were recorded. The level of missing data was
not related to the treatment allocation as demonstrated
by a chi-squared test (Table 5).
Resource use
Table 6 details the mean levels of resource usage per
treatment arm. Participants in the cryotherapy arm had
a mean of 3.59 visits to the GP, nurse or podiatrist for
treatment. The salicylic acid arm participants had a
Table 4 Unit costs for healthcare professionals’ time
Healthcare professional Source Unit of measurement Unit cost Used for
Nurse (GP practice) PSSRU [17] Per hour (minute) in clinic £28.00 (0.47) Administration of cryotherapy/salicylic acid
Nurse (GP practice) PSSRU [17] Per surgery consultation £10 Additional nurse visits
GP PSSRU [17] Per surgery/clinic minute £2.70 Administration of cryotherapy/salicylic acid
GP PSSRU [17] Per surgery consultation lasting 11.7 min £31 Additional GP visits
Community chiropodist/podiatrist PSSRU [17] Per clinic visit £11.00 Administration of cryotherapy/salicylic acid
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(three for both groups) had extra visits to the GP, in
addition to the planned treatment visits. Participants in
the cryotherapy arm had a mean of 0.04 additional visits
to the GP, whilst those in the salicylic acid arm had a
mean of 0.01 additional visits. Eight patients from both
groups had additional visits to a nurse. This resulted in
a mean number of additional nurse visits of 0.05 for the
cryotherapy patients and 0.08 for the salicylic acid
group. Salicylic acid patients received a mean of 1.25
tubes of salicylic acid, whilst cryotherapy patients
received a mean of 3.49 treatments.
Total costs
Table 7 summarizes the mean costs by item of resource
usage, per treatment arm based on the base case analysis.
The mean cost per patient in the cryotherapy and sal-
icylic acid arm was approximately £150 and £49 respec-
tively. The main driver of costs was the healthcare
professionals’ time for treatment administration, with the
average cost per patient being larger in the cryotherapy
group compared to the salicylic acid group (£88.69 vs.
£39.59). The second largest cost for the cryotherapy
group was the cost of treatment itself, which included the
cost of equipment and liquid nitrogen. The average cost
of the cryotherapy treatment per patient was £60.05.
Health outcomes
Details on the results of health outcomes analysis have
been published in the clinical paper of this study [9].
Briefly, 17 of the 119 (14.3%) patients in the salicylic
acid group and 15 of the 110 (13.6%) patients in the
cryotherapy group had complete clearance of plantar
warts at 12 weeks. There was no evidence of a differ-
ence between the salicylic acid and the cryotherapy
groups (difference 0.65, 95% CI: -8.33-9.63, p = 0.89).
Cost-effectiveness
The base case analysis (unadjusted and adjusted results),
demonstrated that there is a significant difference in
total costs between the two treatments. Cryotherapy
costs on average £101.17 more per patient when com-
pared with salicylic acid (Bias corrected and accelerated
(BCA) 95% CI: 85.09-117.26) when using unadjusted
estimates. The cost increased very slightly to £101.21,
(BCA 95% CI 84.18-118.25), when adjusted estimates
were used The treatment effect for cryotherapy is smal-
ler than that of salicylic acid, although not statistically
significant (difference of -0.0065, BCA 95%CI: -0.10-0.08
for the unadjusted analysis and -0.00336, BCA 95% CI:
-0.09-0.08 for the adjusted analysis). In both cases,
cryotherapy is a dominated alternative i.e. it is more
costly and results in a smaller treatment effect compared
with salicylic acid.
Figure 1 shows the incremental costs (unadjusted &
adjusted) and incremental effects for cryotherapy com-
pared with salicylic acid on a cost-effectiveness plane.
While there is little uncertainty around the cost esti-
mates, this is not the case for the treatment effect esti-
mates, where 50% of the simulations fall either side of
the 0 point of x-axis. Figure 2 presents the cost-effec-
tiveness acceptability curve (CEAC). This demonstrates
the probability of cryotherapy being cost-effective given
a specific willingness-to-pay value per cured patient.
Both adjusted and unadjusted data give similar results:
the probability of cryotherapy being cost-effective in
relation to salicylic acid does not exceed 50% at a range
of threshold willingness-to-pay values.
The scenario 2 analysis resulted in similar outcomes
as the first analysis. Cryotherapy is more costly (incre-
mental costs of £101.39, BCA 95% CI: 86.29-117.29) and
less effective (incremental effects of -0.0083, BCA 95%
CI: -0.10-0.08), hence it is a dominated alternative.
Sensitivity analysis
The sensitivity analysis resulted in cryotherapy being
£9.18, BCA 95% CI 7.09-11.26 (£9.17, BCA 95% CI
7.00-11.33) more costly than the salicylic group and
having an incremental treatment effect of -0.0065, BCA
95% CI-0.10-0.08 (-0.0034 BCA 95% CI -0.09-0.08),
based on unadjusted (adjusted) estimates. Cryotherapy is
again more costly than the salicylic acid. This is due to
Table 5 Missing data on resource use items and outcomes
Missing response, n (%) Treatment arm impact on level of missing
data (Pearson chi-squared, p)
Resource use item Cryotherapy (n = 117) Salicylic acid (n = 123)
Additional visits to GP or nurse 35 (30) 34 (28) (0.1511, 0.697)
Treatment visits 8 (7) 3 (2) (2.6528, 0.103)
Number of tubes of Verrugon NA 7 (6) NA
Number of cryotherapy treatments 8 (7) NA NA
Outcome data
Primary outcome 7 (6) 4 (3) (0.1345, 0.714)
NA Not applicable
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made to the clinic, even though the time cost of the
healthcare professional who administered the cryother-
apy was lower (practice nurse vs. GP). This, in conjunc-
tion with the lack of treatment effect, leads to
cryotherapy being a dominated option.
Discussion
Principal findings
The EVerT trial [9] has demonstrated that there is no evi-
dence of a difference in effectiveness between cryotherapy
and salicylic acid at 12 weeks. In fact, cryotherapy appears
to be marginally worse than salicylic acid, however, these
Table 6 Average resource usage
Cryotherapy Salicylic acid Difference
Average number of treatment visits N 109 120
Mean (SE) 3.59 (0.072) 1.94 (0.38) 1.65(p < 0.000)
SD 0.75 0.42
Median (min, max) 4 (1, 5) 2 (1, 4)
Missing (%) 8 (7%) 3 (2%)
Average number of additional GP visits N8 2 8 9
Mean (SE) 0.04 (0.03) 0.01 (0.01) 0.03(p = 0.376)
SD 0.25 0.11
Median (min, max) 0 (0, 2) 0 (0, 1)
Missing (%) 35 (30%) 34 (28%)
Average number of additional nurse visits N8 2 8 9
Mean (SE) 0.05 (0.03) 0.08 (0.04) 0.03(p = 0.530)
SD 0.27 0.34
Median (min, max) 0 (0, 2) 0 (0, 2)
Missing (%) 35 (30%) 34 (28%)
Average number of tubes of Verrugon N NA 116 NA
Mean (SE) NA 1.25 (0.04)
SD NA 0.44
Median (min, max) NA 1 (1, 2)
Missing (%) NA 7 (6%)
Average number of cryotherapy treatments given to patients N 109 NA NA
Mean (SE) 3.49 (0.08) NA
SD 0.80 NA
Median (min, max) 4 (1, 5) NA
Missing (%) 8 (7%) NA
NA Not applicable
Table 7 Costs by item of resource usage
Item Treatment group Mean cost (£) SD (£) Min-Max(£)
Treatment visits (Healthcare professional’s time) Salicylic acid 39.59 35.03 11.00-62.00
Cryotherapy 88.69 74.46 11.00-270.00
Verrugon (inc.pads and plasters) Salicylic acid 8.5 2.91 6.79-13.58
Cryotherapy cost (liquid nitrogen & equipment cost) Cryotherapy 60.05 13.17 17.08-85.40
Additional visit to GP Salicylic acid 0.35 2.84 0.00-31.00
Cryotherapy 1.15 6.57 0.00-62.00
Additional visit to nurse Salicylic acid 0.78 2.98 0.00-20.00
Cryotherapy 0.49 2.31 0.00-20.00
Total costs Salicylic acid 49.22 37.78 17.79-209.79
Cryotherapy 150.39 78.45 50.08-365.40
Difference = 101.17 p < 0.001
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also more expensive than salicylic acid, at an average
incremental cost of approximately £101 per patient. This
evidence results in cryotherapy being dominated (i.e. more
costly, less effective) by salicylic acid. Both methods that
were adopted for the data analysis (complete case and
multiple imputation) resulted in the same conclusion as
above. When excluding the cost of cryotherapy equipment
and liquid nitrogen, and replacing the provision of the
treatment from GP with practice nurse, as part of a sensi-
tivity analysis, cryotherapy remained more expensive than
the salicylic acid.
Figure 1 Cost-effectiveness plane.
Figure 2 Cost-effectiveness acceptability curve.
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This analysis constitutes the first economic evaluation of
treatments for plantar warts conducted based on pri-
mary data. It was conducted alongside a randomised
controlled trial of pragmatic nature; hence the results
should have strong external validity for the everyday
clinical practice for plantar warts treatment in the UK
setting.
The analysis took a narrow NHS perspective. A socie-
tal perspective would have provided a broader picture of
the economic impact of the two treatments for plantar
warts. However, given the lack of difference in effective-
ness between the two treatments, incorporating addi-
tional costs such as those incurred by patients for
travelling to the clinical practice to receive cryotherapy
treatment would have only emphasised the conclusions
of this analysis i.e. cryotherapy is a more costly option
which does not offer additional benefits compared with
salicylic acid.
T h e r ew e r em i s s i n gd a t ao nb o t hr e s o u r c eu s a g ea n d
the primary outcome. Whilst there were high missing
data for self-reported health care use there were much
fewer missing data on the main outcomes and main
costs were much lower (below 10%). We do not think,
therefore, this would have introduced significant bias to
our results. The conclusions of the study could be com-
promised by the lack of these data; however, the analysis
based on the complete cases on primary outcome and
the one based on the multiple imputation, led to similar
conclusions. This increases the confidence that the
results are robust and not affected by the presence of
missing data.
The economic analysis was conducted at 12 weeks
after randomisation. The short timeframe might consti-
tute a study limitation given the recurring nature of
plantar warts. However, given the cure rates were simi-
lar between the two groups at six months it is likely
that that the clinical results gathered over this short
time frame are representative of a medium term follow-
up. It would be of value to examine whether the conclu-
sions of this analysis would still hold at a later time-
point, such as one or two years after patients received
the treatment and whether or not participants used
health care resources at different rates. The only
assumption that could possibly change the conclusions
of this analysis is that patients treated with cryotherapy
have a lower recurrence rate, hence consuming fewer
additional resources for the treatment of the recurring
warts.
We included an Irish site with 13 patients. Whilst in
theory Irish patients may have had a different care path-
w a yt oU Kp a t i e n t si nt h i si n s t a n c ei ti su n l i k e l ya st h e
Irish PI (CM) was an English podiatrist who had pre-
viously treated patients in Huddersfield so we do not
anticipate that using the patients in the economic analy-
sis would have contributed any bias to the results.
Main drivers of the results
By excluding the cryotherapy treatment costs completely
and reducing the cost of the healthcare professional
who administers the treatment, it is made evident that
the results are strongly driven by the lack of effective-
ness as well as the larger number of treatment visits to
the clinic that cryotherapy patients have. When the
costs of the cryotherapy equipment and liquid nitrogen
are included, it is expected to have even more negative
results for the cost-effectiveness of cryotherapy. The
c o m b i n a t i o no fl a c ko fd i f f e r e n c ei ne f f e c t i v e n e s s
between cryotherapy and salicylic acid and higher costs
leads to cryotherapy being dominated by salicylic acid.
Outside of a clinic setting the costs of salicylic acid
would be even lower as it is a self-administered treat-
ment. Consequently, including the costs of visits to a
health care professional as used in the trial will over
estimate the costs of using salicylic acid in usual
practice.
Recommendations for further research
The spectrum of the treatment options for plantar warts
is quite wide, with most of them being over-the-counter
treatments which patients can self-administer. The ben-
efit of this type of administration is that the opportunity
cost of healthcare professionals’ time is reduced or
eliminated completely, which leads to economic advan-
tage. Given the results of EVerT trial which showed no
difference in effectiveness between salicylic acid and
cryotherapy, and the lower costs of salicylic acid, it
would be valuable to have data from randomised clinical
trials on the treatment effects of other over-the-counter
treatments compared with salicylic acid. Even if these
treatments do not prove to be dominant compared with
salicylic acid (i.e. less costly and more effective), from
the economics perspective it would still be relevant to
examine the question on how much more we are pre-
pared to pay for a better cure rate than the salicylic acid.
Conclusions
Self-treatment with salicylic acid is more cost-effective
for the treatment of plantar warts than cryotherapy
administered by a healthcare professional. Whilst
cryotherapy costs on average £101 more per participant
over the 12 week time-frame, while there is no addi-
tional benefit, in terms of proportion of patients healed
compared with salicylic acid. This evidence can contri-
bute to the everyday clinical decision making process on
which treatment should be used for plantar warts. More
importantly, if there is a shared decision making
between the healthcare professional and the patients
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Page 9 of 10themselves on the treatment pathway, this can be based
on the full information provided to the patient that
cryotherapy is not any better than salicylic acid while it
costs more to the NHS.
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